DCM
AEGR

Driehaus Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Driehaus Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,742
Closed -$1.86M – 573
2013
Q3 		$1.86M Sell
21,742
-119,095
-85% -$10.1M 0.07% 287
2013
Q2 		$8.92M Buy
+140,837
New +$7.48M 0.39% 73

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's AEGR Position: Q4 2013 in Review

Driehaus Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 21,742 shares — an estimated $1.86M sold.

Driehaus Capital Management first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $8.92M in Q2 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Driehaus Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Driehaus Capital Management sold 21,742 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $1.86M.
  • Driehaus Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Driehaus Capital Management's Aegerion Pharmaceuticals position peaked at $8.92M in Q2 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Driehaus Capital Management's 13F filing for Q4 2013, filed 13 Feb 2014.